tbuckley/cabot-search huggingface dataset:
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2017
Authors: Candice L. Robinson, José R. Romero, Allison Kempe, Cynthia Pellegrini
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

In October 2016, the Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger-United States, 2017. The 2017 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2016 immunization schedules, in three figures, and footnotes for the figures. These documents can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules/index.html). These immunization schedules are approved by ACIP (https://www.cdc.gov/vaccines/acip/index.html), the American Academy of Pediatrics (https://www.aap.org), the American Academy of Family Physicians (https://www.aafp.org), and the American College of Obstetricians and Gynecologists (http://www.acog.org). Health care providers are advised to use the figures and the combined footnotes together. The full ACIP recommendations for each vaccine, including contraindications and precautions, can be found at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Providers should be aware that changes in recommendations for specific vaccines can occur between annual updates to the childhood/adolescent immunization schedules. If errors or omissions are discovered within the child and adolescent schedule, CDC posts revised versions on the CDC immunization schedule website.
Preadolescent Sports
Authors: Anthony H. Woodward
Journal: JAMA (1974)

<h3>To the Editor.—</h3> After reading Dr. Thornton's article about preadolescent sports (227:418, 1974), I must make the following remarks. The physician watching children playing sports will see injuries. They may be few, but they are definite and obvious harms. In contrast, the benefits of such sports are not at all obvious. I know of no evidence that increasing a child's oxygen consumption by 15% promises him a longer life with fewer diseases. The physician can and must warn of hazards, not promote some future idyllic existence.
Plantar Pressure Measurements
Authors: John P. Barrett
Journal: JAMA (1976)

Objective measurements of forefoot plantar pressure were taken on 25 patients with rheumatoid arthritis. The Harris mat footprint test and the Brand slipper sock test were used to assess both compressive and shearing forces. The Harris mat footprint test is a static test used when the patient is unshod. The Brand slipper sock test is a dynamic test used while the shoe is worn. An experimental sandal was designed and used for the treatment of symptomatic forefoot callosities. The Harris mat footprint test results improved dramatically after the patients had worn an experimental sandal for six months. The Brand slipper sock test results showed marked diminution in the pressure profile while the patients wore the experimental sandal. All of the patients improved in their functional abilities while wearing the experimental sandal. (<i>JAMA</i>235:1138-1139, 1976)
HEMATINEMIA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Handbuch der mikroskopischen Anatomie der Menschen.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Evaluation of Tc-99m Cystine A New Renal Radiopharmaceutical
Authors: M Misra, B K Das, S Gambhir, B R Mittal, A B Sewatkar, S Ghosh, S N Banerjee
Journal: Clinical Nuclear Medicine (1994)

Tc-99m cystine has been proved to be a good renal agent in animals. Its clinical evaluation has not been reported. In this study, Tc-99m cystine is used for evaluation of renal function in normal subjects and patients with chronic renal failure as well as in renal transplant patients. The results are compared with similar studies using Tc-99m DTPA and Tc-99m GHA. The clearance values also are compared with I-131 OIH. The results show that Tc-99m cystine has good radiopharmaceutical characteristics suitable for evaluation of both renal function as well as morphology.
Food
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peroral Cholecystoscopy
Authors: R Fujita, N Hirata, Y Fujita
Journal: Endoscopy (1989)

Three cases of peroral cholecystoscopy was reported. Dilatation of the cystic duct ranged from 8.5 mm to 10.0 mm in diameter, permitting passage of a 4.5 mm diameter baby 'scope. Endoscopic lithotripsy was performed without difficulty.
US Cigar Smokers’ Preferences
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Approaches to Chemoprevention of Lung Cancer Based on Carcinogens in Tobacco Smoke
Authors: Stephen S. Hecht
Journal: Environmental Health Perspectives (1997)

Chemoprevention may be one way to prevent lung cancer in smokers who are motivated to quit but cannot stop.The approach to chemoprevention of lung cancer described in this article is based on an understanding of the lung carcinogens present in tobacco smoke.The available data indicate that the compounds in cigarette smoke most likely involved in the induction of lung cancer in humans are the complex of polynuclear aromatic hydrocarbons typified by benzo[a]pyrene (B[a]P) and the tobacco-specific nitrosamine 4-(methyinitrosamino)-143-pyridyl-1butanone (NNK).A large number of compounds are now available that inhibit lung tumorigenesis by Bla]P or NNK in rodents.Inhibition of NNK-induced lung carcinogenesis by phenethyl isothiocyanate (PEITC) and inhibition of Bla]P-induced lung carcinogenesis by benzyl isothiocyanate (BITC) are discussed as examples.Studies with PEITC in rodents clearly demonstrate that it inhibits NNK-induced lung tumorigenesis by inhibiting the metabolic activation of NNK.Similar changes appear to occur in humans according to data generated in smokers who ate watercress, a source of PEITC.It is likely that mixtures of chemopreventive agents with activity against carcinogens in tobacco smoke, such as NNK and B[aJP, will be useful in chemoprevention of lung cancer in smokers.Furthermore, there is a need to develop suppressing agents for lung cancer that might be applicable in both smokers and ex-smokers.-
MEMBERSHIP OF EDUCATIONAL COMMITTEES (AS OF OCT 1, 1980)
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Experimental Silicosis: A Model for the Study of Inflammatory Pulmonary Reticulin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice
Authors: Pascal Bernatchez, Arpeeta Sharma, Philip M. Bauer, Ethan Marin, William C. Sessa
Journal: Journal of Clinical Investigation (2012)

In the Results section, in the paragraph titled "Cavnoxin decreases both BP and vascular tone in an eNOS-dependent manner," the figure citation was incorrect.The correct sentence appears below.Cavnoxin, but not AP, reduced KCl-mediated contractility of the vessels and the contractile response to the α adrenoceptor agonist, phenylephrine (PE) (Figure 5A).The authors regret the error.
Editorial Board
Authors: Bruce Thiers, Dirk Elston, Detra Davis, Jack Lesher, Kenneth Katz, Mary Spellman, Jeffrey Weinberg, Dermatologic Surgery, Clifford Perlis, Julie Prendiville, Frcpc Dermatopathology, John Maize, Robert Dellavalle, J Smith, Editors Emeritus, Richard Dobson, Jeffrey Bernhard, Calvin Mccall, Brett Sloan, James Solomon, Stephen Tyring, George Hruza, Pediatric Dermatology, Kelly Cordoro, Dermatopathology Carlson, Tammie Ferringer, Cyberdermatology Consultant, Daniel Siegel, Clara Kim, Salvador Arias-Santiago, April Armstrong, Bryan Anderson, Trisha Beute, John Binhlam, Diana Bolotin, Markus Braun-Falco, Nooshin Brinster, Patrick Carrington, Zoe Draelos, Nananamibia Duffy, Laura Ferris, David Fivenson, Joel Gelfand, Camille Introcaso, Nathaniel Jellinek, Jonathan Kantor, Matthew Kanzler, Kevin Kia, Nikki Levin, J Am, Acad Dermatol
Journal: Journal of the American Academy of Dermatology (2013)
Inclusion bodies in measles encephalitis
Authors: J. M. Adams
Journal: JAMA (1966)

New evidence is presented for the first time to uphold the concept that the measles virus is primarily responsible for the signs, symptoms, and pathological changes in measles encephalitis. The presence of cytoplasmic or nuclear inclusion bodies, or both, in brain tissues of 15 patients from 20 cases supports the direct viral etiology of this disease. Multinucleated giant cells, an additional hallmark of the measles virus, have been found in five patients. This series of 20 fatal cases, the largest in the literature, has been collected from 12 different sources in Mexico and the United States. Greenfield<sup>1</sup>cites the earliest case of measles encephalitis in England as that reported by Lucas<sup>2</sup>in 1790 who wrote "An Account of Uncommon Symptoms Following the Measles." The original pathological descriptions of myelitis following measles were made by Barlow and Penrose in 1886.<sup>3</sup>Not until the 1920's were clear reports of
<i>QuickStats</i>: Percentage* of Adults Aged ≥18 Years Who Are Very Worried about Medical Costs,† by Home Ownership§ and Age Group — National Health Interview Survey,¶ United States, 2015
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In 2015, 15.6% of adults who lived in rental houses/apartments were very worried about paying for medical costs, compared with 8.7% of adults who lived in family-owned homes. Adults aged 18-39 years who lived in rental homes were more likely than those in family-owned homes to be very worried about paying medical costs (12.9% versus 8.0%). Among adults aged 40-64 years and ≥65 years, renters were twice as likely as home owners to be very worried about medical costs (22.3% versus 11.4%, and 8.6% versus 4.0%, respectively).
Acanthosis nigricans and pituitary tumors. Report of eight cases
Authors: J. Brown
Journal: JAMA (1966)

Findings in eight patients with acanthosis nigricans and pituitary tumors, seven of whom had acromegaly or gigantism, emphasize the association of this dermatosis with pituitary disease. The sex incidence was equal, and their ages varied between 15 and 46 years. Two male patients had diabetes mellitus; three of four female patients had hypertrichosis, and all four female patients had amenorrhea. Obesity was not a constant feature. The clinical and histological findings were similar to those in acanthosis nigricans associated with other diseases. The occurrence of acanthosis nigricans with pituitary tumors as well as with other endocrine diseases, drugs, and total lipodystrophy raises the question of a possible hormonal or metabolic relationship of this dermadrome.
In vitro Models and Methods for Bioassay and Studies of Cellular Mechanisms
Authors: Sidney Belman, Bruce Casto, C Flessel, Bernard Lane, Lawrence Loeb, Toby Rossman, Michael Sirover, Harri Vainio, Robert Whiting
Journal: Environmental Health Perspectives (1981)

Relationship Between In Vivo and In Vitro TestingThis report discusses the use of in vitro systems to detect metal carcinogens and to provide infornation on the mechanisms of metal carcinogenesis.The use of in vivo systems is also discussed, where they may provide additional information.Even though no single system has proven adequate for the definitive identification of all metal mutagens and carcinogens, the aggregate results of these studies indicate that the combined use of several systems may provide a valuable, initial screen for metals and their compounds.It is now imperative to evaluate more complex aggregates and mixtures of metals and their compounds that are environ- mentally ubiquitous (1).Metals appear to behave similarly to other carcinogens in cell transformation tests; however, they are frequently negative in bacterial mutagenesis revertant assays.In addition to rapid screening, cellular systems are particularly advantageous for analyzing the mechanism ofmetal mutagenesis and carcinogenesis.It is only in such systems that one may be able to study the mechanism and specificity of metal- induced cellular alterations which may be causative factors in neoplasia.The physiological chemistry of different metals may vary widely.For example,
Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).
Authors: Chiara Lazzari, Silvia Novello, Sandro Barni, Michele Aieta, Filippo De Marinis, Tommaso De Pas, Francesco Grossi, Manlio Mencoboni, Alessandra Bearz, Irene Floriani, Valter Torri, Alessandra Bulotta, Julia Grigorieva, Joanna Roder, Claudio Doglioni, Heinrich Roder, Luisella Righi, Silvia Foti, Angela Bachi, Vanesa Gregorc
Journal: Journal of Clinical Oncology (2013)

LBA8005 Background: Second-line therapy for advanced NSCLC patients (pts) after progression on platinum-based regimens typically employs CT or E. Improved PFS in E-treated pts is associated with EGFR sensitizing mutations. However, a test for optimizing treatment in pts with wild-type or unknown EGFR mutation status or squamous histology is of clinical value. VeriStrat (VS) is a serum protein test that assigns "good" (VSG) or "poor" (VSP) classification and has demonstrated prognostic and predictive utility. PROSE is a multicenter prospective randomized biomarker validation trial, designed to evaluate the ability of VS to predict survival in second-line NSCLC pts treated with E or CT. It is the first completed prospective randomized biomarker validation trial following the MARVEL design (Freidlin et al. JNCI. 2010). Methods: 285 pts, stratified by ECOG-PS, smoking, and blinded pretreatment VS classification, were randomized 1:1 to receive E or CT at standard doses. Primary endpoint was overall survival (OS) and the primary hypothesis was significant interaction between VS status and treatment. Sample size was calculated based on an estimated 65%/35% VSG:VSP ratio and hazard ratio (HR) for interaction of 2.35, with a 2-sided α=0.05 and 90% power. Results: 285 pts were randomized and 263 (129 CT, 134 E) included in the per protocol primary analysis. 68% of pts in CT arm and 72% in E arm were classified as VSG. Analysis was performed at 226 events. The trial reached its primary objective of significant interaction between treatment and VeriStrat classification with an interaction p value of 0.037. Pts in the VSP group performed worse on E compared to CT (HR: 1.72, 95% CI: 1.08-2.74); there was no significant difference in OS between treatments in the VSG group (HR: 1.09, 95% CI:0.79-1.50). 194/198 pts with histologic diagnosis had tissue available for EGFR and KRAS mutations. Conclusions: The results suggest that VS status is predictive of differential OS benefit for E versus CT in second line setting, complementing the result from a retrospective analysis of NCIC BR.21 where the prognostic behavior of VS was established (Carbone et al. JTO. 2012). Clinical trial information: NCT00989690.
Chorionic Tumors
Authors: R S Berkowitz, D P Goldstein
Journal: New England Journal of Medicine (1996)

Chorionic tumors, or gestational trophoblastic diseases, originate from placental tissues and are among the rare human tumors that can be cured even in the presence of widespread metastasis.14 Gestational trophoblastic diseases include a spectrum of interrelated tumors, including complete and partial hydatidiform mole, placental-site trophoblastic tumor, and choriocarcinoma, that vary in their propensity for local invasion and spreading. Although persistent gestational trophoblastic tumors develop most commonly after a molar pregnancy, they may follow any gestation. This article concentrates on recent advances in the understanding of the pathogenesis, natural history, and treatment of gestational trophoblastic diseases and describes our current . . .
Profiling of routine serum parameters and AFP evolution in cirrhosis following HCVeradication for stratification of HCC risk: a trajectory clustering analysis from the ANRS CO12 CirVir cohort
Authors: Pierre Nahon, Layese Richard, Carole Cagnot, Stanislas Pol, Tarik Asselah, Etienne Audureau
Journal: Journal of Hepatology (2020)